RT Journal Article SR Electronic T1 A practical technique for clinicians to approximate platelet function after fifteen-minutes using thromboelastography JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.10.20033860 DO 10.1101/2020.03.10.20033860 A1 Sharp, Elliott A1 Fludder, Vanessa YR 2020 UL http://medrxiv.org/content/early/2020/03/13/2020.03.10.20033860.abstract AB Background Point-of-care platelet function tests are used by anaesthetists and surgeons to create risk management plans for patients who have recently taken antiplatelet medication. Thromboelastography (TEG), one method of determining platelet function, sometimes takes >60 minutes to produce results. Previous studies have shown a novel parameter, area under the curve at 15 minutes (AUC15), correlates with clinical outcomes but used privately-owned, custom-made software to calculate AUC15. This study aimed to create a formula that clinicians can use to approximate AUC15 which correlates to the most widely used measure of platelet function, percentage of platelet aggregation.Methods Platelet function after 15 minutes can be approximated by the equation: AUC15 = 225(tan(θ)) where θ = α(MAADP/MAThrombin). A retrospective database review was performed on eligible platelet function tests that assessed ADP receptor inhibition on a TEG 6s Hemostasis Analyzer (Haemonetics®) across 15 months. Results were analysed using a bivariate scatter plot with linear regression line and a two-tailed Pearson correlation coefficient was calculated.Results Forty-seven tests were retrieved, of which, forty-five were eligible for analysis. Pearson two-tailed correlation coefficient showed that AUC15 correlated significantly with percentage of platelet aggregation (R = 0.748, 95% CI [0.582, 0.854], p < 0.001).Conclusion This study creates the first practical method for clinicians to approximate platelet function on TEG analysers after 15 minutes, instead of >60 minutes, using routinely generated outputs and a calculator. Clinicians who use this method will afford themselves more time to create risk management plans for patients which may improve patient outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request to the corresponding author.ADPadenosine diphosphatePFTPlatelet function testsTEGThromboelastographyAUC15Area under the curve at 15 minutesMAMaximum amplitudeα angleAngle of thrombin curve between 2-20mm amplitudeR timeLatency time between start of test until 2mm amplitude on the thrombin curve is achievedθ angleAn approximation of the α angle for the ADP curve